Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma

He Xia120 enrolled

Overview

This is a randomized Phase III study to evaluate efficancy of weekly cisplatin or nedaplatin concurrent with Intensity-modulated radiation therapy in Nasopharyngeal Carcinoma (NPC).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Nasopharyngeal Carcinoma

Interventions

NedaplatinDRUG

Nedaplatin combine with IMRT

CisplatinDRUG

Cisplatin combine with IMRT

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathologically confirmed untreated NPC patients * T1-2N1-3M0 or T3-4NxM0 * 18-70 years old * with MRI examinations * ECOG ≤ 2 * With written consent Exclusion Criteria: * With a second cancer * Pregnancy * With other severe diseases (blood,liver ,kidney or heart diseases) * Could not be staged properly * Without written consent

Outcomes

Primary Outcomes

Response rate

Time frame: 2 years

Progress-free survival

Time frame: 2 years

Secondary Outcomes

Tumor response

Time frame: radiotherapy in 2 week、4 week、7 week

Overall survival

Time frame: 2 years

Central Contacts

Li Yin, M.D. Ph.D.

CONTACT

+8613913909043 yinli7878@sina.com

Pengwei Yan, M.M.

CONTACT

+8613815888775 179032794@qq.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.